International Assets Investment Management LLC Buys 39,820 Shares of Anixa Biosciences, Inc. (NASDAQ:ANIX)

International Assets Investment Management LLC grew its stake in Anixa Biosciences, Inc. (NASDAQ:ANIX) by 274.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 54,320 shares of the company’s stock after purchasing an additional 39,820 shares during the quarter. International Assets Investment Management LLC owned approximately 0.17% of Anixa Biosciences worth $2,110,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. US Bancorp DE raised its position in shares of Anixa Biosciences by 3,312.3% in the first quarter. US Bancorp DE now owns 13,649 shares of the company’s stock valued at $37,000 after purchasing an additional 13,249 shares during the period. Virtu Financial LLC bought a new position in Anixa Biosciences during the second quarter worth about $45,000. Dakota Wealth Management bought a new position in Anixa Biosciences during the third quarter worth about $49,000. Tower Research Capital LLC TRC increased its position in Anixa Biosciences by 397.7% during the third quarter. Tower Research Capital LLC TRC now owns 15,763 shares of the company’s stock worth $52,000 after acquiring an additional 12,596 shares during the period. Finally, B. Riley Wealth Advisors Inc. bought a new position in Anixa Biosciences during the third quarter worth about $80,000. 29.13% of the stock is owned by institutional investors.

Insider Buying and Selling at Anixa Biosciences

In other news, Director Arnold M. Baskies bought 10,000 shares of the firm’s stock in a transaction on Friday, March 15th. The shares were purchased at an average cost of $3.63 per share, with a total value of $36,300.00. Following the acquisition, the director now directly owns 110,000 shares in the company, valued at $399,300. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, CEO Amit Kumar bought 30,000 shares of the firm’s stock in a transaction on Friday, March 15th. The shares were purchased at an average cost of $3.22 per share, with a total value of $96,600.00. Following the acquisition, the chief executive officer now directly owns 491,925 shares in the company, valued at $1,583,998.50. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Arnold M. Baskies bought 10,000 shares of the firm’s stock in a transaction on Friday, March 15th. The stock was purchased at an average cost of $3.63 per share, for a total transaction of $36,300.00. Following the completion of the acquisition, the director now owns 110,000 shares in the company, valued at $399,300. The disclosure for this purchase can be found here. Insiders have bought a total of 55,009 shares of company stock valued at $182,130 in the last ninety days. 22.60% of the stock is currently owned by company insiders.

Anixa Biosciences Stock Performance

NASDAQ:ANIX opened at $3.12 on Friday. Anixa Biosciences, Inc. has a 52 week low of $2.75 and a 52 week high of $5.13. The firm has a market cap of $99.53 million, a price-to-earnings ratio of -9.18 and a beta of 0.84. The firm’s 50-day simple moving average is $3.46 and its 200 day simple moving average is $3.63.

Anixa Biosciences (NASDAQ:ANIX) last released its earnings results on Tuesday, March 12th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Sell-side analysts anticipate that Anixa Biosciences, Inc. will post -0.44 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Anixa Biosciences in a research report on Thursday, March 21st.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.